- Home
- FICO vs MIST Comparison
FICO vs MIST Comparison
Compare FICO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FICO | MIST |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 176.3M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FICO | MIST |
|---|---|---|
| Price | $1,105.04 | $1.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $1,944.42 | $8.50 |
| AVG Volume (30 Days) | 335.0K | ★ 1.4M |
| Earning Date | 04-28-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 6.61 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.68 | $1,653.36 |
| Revenue Next Year | $17.15 | $12.32 |
| P/E Ratio | $169.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1,068.67 | $0.63 |
| 52 Week High | $2,217.60 | $3.06 |
Technical Indicators
Market Signals| Indicator | FICO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 27.63 |
| Support Level | $1,068.67 | N/A |
| Resistance Level | $1,562.48 | $1.79 |
| Average True Range (ATR) | 63.20 | 0.10 |
| MACD | -15.24 | -0.03 |
| Stochastic Oscillator | 8.07 | 1.02 |
Price Performance
Historical ComparisonAbout FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).